Tags

Type your tag names separated by a space and hit enter

Treatment of hepatitis E virus.
Curr Opin Infect Dis. 2016 12; 29(6):639-644.CO

Abstract

PURPOSE OF REVIEW

Over the last 10 years, it has become apparent that hepatitis E virus (HEV) is a pathogen of global significance. In contrast to HEV in the developing world, HEV in developed countries is caused by HEV genotypes 3 and 4, which are enzoonotic with a porcine primary host and cause both acute and chronic infection. Chronic infection occurs in the immunosuppressed, including transplant recipients, and untreated can cause rapidly progressive cirrhosis.

RECENT FINDINGS

Ribavirin has been used successfully to treat acute hepatitis E in high-risk patients. Ribavirin monotherapy is the treatment of choice for patients chronically infected with HEV, with sustained virological response (SVR) of approximately 85%. A minority of chronically infected patients fail to achieve SVR with ribavirin monotherapy, possibly because of viral mutants. The treatment of patients who fail to achieve SVR with ribavirin monotherapy is problematic.

SUMMARY

Ribavirin is an effective treatment for hepatitis E, but further studies are required to determine which other antiviral agents are of clinical utility in treating HEV in the minority of patients who do not respond to ribavirin.

Authors+Show Affiliations

aRoyal Cornwall Hospital; European Centre for Environment and Human Health, University of Exeter, Truro, UK bDepartments of Nephrology and Organ Transplantation, CHU Rangueil, INSERM U1043, IFR-BMT, Université Paul Sabatier, Toulouse, France.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27607911

Citation

Dalton, Harry R., and Nassim Kamar. "Treatment of Hepatitis E Virus." Current Opinion in Infectious Diseases, vol. 29, no. 6, 2016, pp. 639-644.
Dalton HR, Kamar N. Treatment of hepatitis E virus. Curr Opin Infect Dis. 2016;29(6):639-644.
Dalton, H. R., & Kamar, N. (2016). Treatment of hepatitis E virus. Current Opinion in Infectious Diseases, 29(6), 639-644.
Dalton HR, Kamar N. Treatment of Hepatitis E Virus. Curr Opin Infect Dis. 2016;29(6):639-644. PubMed PMID: 27607911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of hepatitis E virus. AU - Dalton,Harry R, AU - Kamar,Nassim, PY - 2016/10/27/pubmed PY - 2018/1/4/medline PY - 2016/9/9/entrez SP - 639 EP - 644 JF - Current opinion in infectious diseases JO - Curr Opin Infect Dis VL - 29 IS - 6 N2 - PURPOSE OF REVIEW: Over the last 10 years, it has become apparent that hepatitis E virus (HEV) is a pathogen of global significance. In contrast to HEV in the developing world, HEV in developed countries is caused by HEV genotypes 3 and 4, which are enzoonotic with a porcine primary host and cause both acute and chronic infection. Chronic infection occurs in the immunosuppressed, including transplant recipients, and untreated can cause rapidly progressive cirrhosis. RECENT FINDINGS: Ribavirin has been used successfully to treat acute hepatitis E in high-risk patients. Ribavirin monotherapy is the treatment of choice for patients chronically infected with HEV, with sustained virological response (SVR) of approximately 85%. A minority of chronically infected patients fail to achieve SVR with ribavirin monotherapy, possibly because of viral mutants. The treatment of patients who fail to achieve SVR with ribavirin monotherapy is problematic. SUMMARY: Ribavirin is an effective treatment for hepatitis E, but further studies are required to determine which other antiviral agents are of clinical utility in treating HEV in the minority of patients who do not respond to ribavirin. SN - 1473-6527 UR - https://www.unboundmedicine.com/medline/citation/27607911/Treatment_of_hepatitis_E_virus_ L2 - https://doi.org/10.1097/QCO.0000000000000316 DB - PRIME DP - Unbound Medicine ER -